{"id":192311,"date":"2026-10-26T03:09:14","date_gmt":"2026-10-26T03:09:14","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/192311\/"},"modified":"2026-10-26T03:09:14","modified_gmt":"2026-10-26T03:09:14","slug":"glp-1-drugs-a-22-billion-market-in-china-india-and-brazil-by-2035-etpharma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/192311\/","title":{"rendered":"GLP-1 Drugs: A $22 Billion Market in China, India, and Brazil by 2035, ETPharma"},"content":{"rendered":"<p>                                        <img fetchpriority=\"high\" decoding=\"async\" width=\"590\" height=\"442\" class=\"unveil\" loading=\"eager\" style=\"width:100%;max-height:100%\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/10\/135172349.cms.jpeg\" captionrendered=\"1\" alt=\"\"\/>Bengaluru: The combined China-India-Brazil market for weight-loss drugs could grow to $22 billion by 2035 from $6.6 billion currently, <a id=\"30319740\" type=\"Denny\" weightage=\"20\" keywordseo=\"J-P-Morgan\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/j.p.+morgan\" rel=\"nofollow noopener\" target=\"_blank\">J.P. Morgan<\/a> estimated, as improving <a id=\"32301540\" type=\"Denny\" weightage=\"20\" keywordseo=\"affordability\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/affordability\" rel=\"nofollow noopener\" target=\"_blank\">affordability<\/a> and broader access drive adoption in largely untapped patient populations.<\/p>\n<p>The addressable market could grow at an annual rate of 15% through 2035, J.P. Morgan analysts led by Yang Huang said in a note on Friday, given the countries&#8217; large diabetes and obesity burdens.<\/p>\n<p><a id=\"27684315\" type=\"Denny\" weightage=\"20\" keywordseo=\"GLP-1-drugs\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/glp-1+drugs\" rel=\"nofollow noopener\" target=\"_blank\">GLP-1 drugs<\/a>, such as <a id=\"26646230\" type=\"Denny\" weightage=\"20\" keywordseo=\"Novo-Nordisk\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/novo+nordisk\" rel=\"nofollow noopener\" target=\"_blank\">Novo Nordisk<\/a>&#8216;s Ozempic and Wegovy and <a id=\"26542286\" type=\"Denny\" weightage=\"20\" keywordseo=\"Eli-Lilly\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/eli+lilly\" rel=\"nofollow noopener\" target=\"_blank\">Eli Lilly<\/a>&#8216;s Zepbound, have become some of the most sought-after medicines for weight-loss and <a id=\"29815696\" type=\"Denny\" weightage=\"20\" keywordseo=\"diabetes-treatment\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/diabetes+treatment\" rel=\"nofollow noopener\" target=\"_blank\">diabetes treatment<\/a> globally.<\/p>\n<p>China and India are home to some of the world&#8217;s largest diabetes patient populations, accounting for more than 25% and 15% of global diagnosed cases, respectively, while about 12% of Brazilian adults have diabetes, according to J.P. Morgan.<\/p>\n<p>The three countries also face a growing obesity burden. China&#8217;s overweight and obese population could exceed 65% by 2030, while India&#8217;s adult obesity rate is projected to reach 11% by 2035.<\/p>\n<p>&#8220;GLP-1 is transitioning from a developed-market growth theme to a broader global access story&#8230;&#8221; the analysts said.<\/p>\n<p>&#8220;With patent cliffs, generic launches and policy-engineered price cuts now improving GLP-1 affordability, the three markets are converging on the same destination.&#8221;<\/p>\n<p>UNDER-TAPPED MARKETSGLP-1&#8217;s uptake in many <a id=\"27465411\" type=\"Denny\" weightage=\"20\" keywordseo=\"emerging-markets\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/emerging+markets\" rel=\"nofollow noopener\" target=\"_blank\">emerging markets<\/a> has remained low due to affordability concerns. Penetration is below 0.1% in China and under 0.2% in India, versus 4%-5% in the US, according to the note.<\/p>\n<p>While Brazil is currently the largest of the three markets, obesity-drug penetration is projected to reach only 7%-8% of its obese population by 2035, compared with about 30% in the US.<\/p>\n<p>J.P. Morgan expects China to overtake Brazil by 2027, with its market reaching $13.7 billion by 2035, versus $8 billion for Brazil, supported by its large diabetes burden and wider reimbursement for GLP-1 therapies.<\/p>\n<p>For India, the smallest of the three markets, conservative attitudes toward GLP-1 drugs, alongside affordability concerns, remain key barriers to adoption, J.P. Morgan said, as hesitancy around injectables and slow-shifting cultural attitudes persist.<\/p>\n<p>The brokerage highlighted China&#8217;s Innovent, <a id=\"18318925\" type=\"DOMAIN\" weightage=\"20\" keywordseo=\"divis-laboratories\" botkeyword=\"\" source=\"ET\" sourcekeytype=\"COMPANY\" meta.keywordsubtype=\"EQ\" meta.aliasname=\"divi&#039;s laboratories\" meta.entityname=\"Divi&#039;s Laboratories Ltd.\" meta.entityid=\"3635\" meta.seoname=\"divis-laboratories-ltd\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/divi%27s+laboratories\" rel=\"nofollow noopener\" target=\"_blank\">Divi&#8217;s Laboratories<\/a> and <a id=\"13873800\" type=\"DOMAIN\" weightage=\"20\" keywordseo=\"torrent-pharmaceuticals\" botkeyword=\"\" source=\"ET\" sourcekeytype=\"COMPANY\" meta.keywordsubtype=\"EQ\" meta.aliasname=\"torrent pharmaceuticals\" meta.entityname=\"Torrent Pharmaceuticals Ltd.\" meta.entityid=\"8492\" meta.seoname=\"torrent-pharmaceuticals-ltd\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/torrent+pharmaceuticals\" rel=\"nofollow noopener\" target=\"_blank\">Torrent Pharmaceuticals<\/a> in India, and Brazil&#8217;s RD Saude as its key stocks to play the GLP-1 growth theme.<\/p>\n<p>(Reporting by Joel Jose in Bengaluru; Editing by Janane Venkatraman)\n                                                                    <\/p>\n<p>                                    Published On Oct 24, 2026 at 07:50 PM IST<\/p>\n<p>\n                Join the community of 2M+ industry professionals.<br \/>\n                Subscribe to Newsletter to get latest insights &amp; analysis in your inbox.\n            <\/p>\n<p>                    All about ETPharma industry right on your smartphone! <\/p>\n<p>                        <img decoding=\"async\" loading=\"lazy\" width=\"90\" height=\"90\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/10\/1792984154_318_pharma_barcode.png\" alt=\"\"\/>                        <\/p>\n","protected":false},"excerpt":{"rendered":"Bengaluru: The combined China-India-Brazil market for weight-loss drugs could grow to $22 billion by 2035 from $6.6 billion&hellip;\n","protected":false},"author":2,"featured_media":192312,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[84909,86594,18205,86595,276,44184,1166,86593,13738,272,34277,40472],"class_list":["post-192311","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-affordability","tag-china-india-brazil","tag-diabetes-treatment","tag-divis-laboratories","tag-eli-lilly","tag-emerging-markets","tag-glp-1-drugs","tag-j-p-morgan","tag-market-growth","tag-novo-nordisk","tag-torrent-pharmaceuticals","tag-weight-loss-market"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117505016641201176","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/192311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=192311"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/192311\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/192312"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=192311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=192311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=192311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}